Another recent study, combining CRISPR/Cas9 loss-of-function screens, super-resolution microscopy, and biochemistry, pinpointed MFN2 and MARCH5 as primary modes of AML resistance to BH3 mimetic drugs [127]. This evidence concerns the gene MARCHF5 and acute myeloid leukemia.